Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikhil A Shukla

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Lung Cancer Management|April 8, 2020
Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiationNikhil A Shukla, Nasser H Hanna
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 7, 2024
Response to Letter to the EditorSoyeong Jun, Nikhil A Shukla, Nasser H Hanna, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 23, 2008
Airway epithelial versus immune cell Stat1 function for innate defense against respiratory viral infectionLaurie P Shornick, Audrey G Wells, Yong Zhang, et al.
Cancer|November 24, 2022
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029Tareq Salous, Nikhil A Shukla, Sandra K Althouse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 6, 2024
Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLCSoyeong Jun, Nikhil A Shukla, Greg Durm, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Lung Cancer Management|April 8, 2020
Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiationNikhil A Shukla, Nasser H Hanna
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 7, 2024
Response to Letter to the EditorSoyeong Jun, Nikhil A Shukla, Nasser H Hanna, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 23, 2008
Airway epithelial versus immune cell Stat1 function for innate defense against respiratory viral infectionLaurie P Shornick, Audrey G Wells, Yong Zhang, et al.
Cancer|November 24, 2022
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029Tareq Salous, Nikhil A Shukla, Sandra K Althouse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 6, 2024
Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLCSoyeong Jun, Nikhil A Shukla, Greg Durm, et al.
Pageof 1